Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.